FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Écoutez des podcasts informatifs sur les traitements du cancer, les approbations de produits et les mises à jour de sécurité en oncologie et développement de médicaments.

Épisodes récents

Nov 18, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma

3 mins

Nov 14, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma

4 mins

Aug 16, 2024

FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer

5 mins

Jul 2, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic RET fusion-positive thyroid cancer

4 mins

Jun 17, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation

4 mins